|Bid||55.00 x 900|
|Ask||59.64 x 1000|
|Day's Range||58.53 - 59.17|
|52 Week Range||14.60 - 63.73|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.14|
GENEVA-- -- First quarter sales of $1.8 billion, flat to last year; an increase of 4% constant currency Healthy momentum in Surgical business, with 2% growth and 7% constant currency growth Full year 2019 outlook of 3% to 5% constant currency net sales growth and 17% to 18% core operating margin Regulatory News: Alcon , the global leader in eye care, today reported selected financial results for the ...
Alcon Inc. (ALC) is a leading eye care company. Investors may be most familiar with its Opti- Free branded contact lens solution, but it also has exposure to the surgical area. The business is divided into two segments, surgical (about 55% of sales) and vision care (45% of sales).
GENEVA-- -- Large scientific program will reinforce the ongoing clinical and patient benefits of its robust portfolio Highlights include new product launches in phacoemulsification, visualization for the Cataract Refractive Suite and innovations in intraoperative aberrometry and AT-IOLs Onsite events for surgeons demonstrate Alcon’s continued commitment to world-class training, education Alcon, the ...
Alcon , the global leader in eye care dedicated to helping people see brilliantly, today announced it will participate in the following conferences:
Health-care earnings begin in earnest this week. Centene Corp. reported on Tuesday, and Anthem Inc., Biogen Inc., Boston Scientific Corp. and Novartis AG are set to report Wednesday.
Alcon (ALC.SW) (ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today that it will provide a trading update and host a conference call on Thursday, May 16, at 3:00 p.m. Central European Time / 8 a.m. Central Time for the quarter ended March 31, 2019. This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Alcon. This publication may contain certain forward-looking statements concerning the Company and its business.
Newly spun off from Novartis, the eye-care giant has strong growth potential and is better off as an independent company.
This weekend's Barron's cover story offers a look at a company set to shake up health care. Other featured articles examine prospects for oil drillers as takeover targets and for dividend growth stocks. ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 11) Edap Tms SA (NASDAQ: EDAP ) Down In The Dumps (Biotech ...
Novartis news about the company's spin-off of Alcon has NVS stock down on Tuesday.Source: Shutterstock Novartis (NYSE:NVS) announced on Tuesday that it has completed its spin-off of Alcon. This has the stock now trading on the New York Stock Exchange under the stock ticker of "ALC." It is also trading under this ticker on the SIX Swiss Exchange. There is no change to the tickers for NVS stock on either exchange.The Novartis news about the spin-off had the company completing the action through a dividend-in-kind distribution. This means that the Alcon (NYSE:ALC) spin-off saw investors in NVS stock gain shares of ALC stock. The rate was one share of ALC stock for each five shares of NVS stock held by an investor.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNovartis notes that the spin-off of Alcon has the company better aligning its portfolio with those of its peers in the pharmaceutical industry. This will allow to to focus its capital allocation and management attention on medicines. * 8 Risky Stocks to Watch as Earnings Season Kicks Off "At Novartis, we continue to reimagine ourselves as a leading medicines company powered by breakthrough medicines, data science and advanced therapy platforms," Vas Narasimhan, CEO of Novartis, said in a statement. "We are well positioned for the future and I am excited for our associates, our investors, and most importantly for patients."NVS stock was down 11% as of Tuesday morning, but is up nearly 13% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Medical Marijuana Stocks to Cure Your Portfolio * 8 Best Stocks to Buy for an April Rally * Top 20 Stocks to Buy for 20-Somethings! As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Novartis News: NVS Stock Sinks Following Alcon Spin-Off appeared first on InvestorPlace.
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced its debut as an independent, publicly traded company and the completion of its separation from Novartis.